Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study

Main Article Content

Loretta Fiorillo
Emily Becker
Raul de Lucas
Anna Belloni-Fortina
Peter Maes
Rajneet K. Oberoi
Maria Paris
Wendy Zhang
Zuoshun Zhang
Lisa Arkin
Dawn Nicewarner


Moderate to Severe Plaque Psoriasis, Apremilast, Efficacy, Safety


1. Papp K, et al. J Am Acad Dermatol. 2015;73:37-49.

2. Paul C, et al. Br J Dermatol. 2015;173:1387-1399.

Most read articles by the same author(s)